--- title: "BiomX | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/287118860.md" datetime: "2026-05-20T20:55:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287118860.md) - [en](https://longbridge.com/en/news/287118860.md) - [zh-HK](https://longbridge.com/zh-HK/news/287118860.md) --- # BiomX | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -7.38. EBIT: As of FY2026 Q1, the actual value is USD -1.104 B. ### Financial Performance Summary #### Net Loss Net loss was - $19.1 million for the three months ended March 31, 2026, compared to - $7.7 million for the three months ended March 31, 2025. #### Operating Loss Operating loss was - $1.3 million for the three months ended March 31, 2026, marking an 83% decrease from - $7.8 million for the three months ended March 31, 2025. #### Research and Development (R&D) Expenses, Net R&D expenses, net, were - $0.3 million for the three months ended March 31, 2026, a decrease of approximately $5.6 million from $5.3 million for the three months ended March 31, 2025. #### General and Administrative Expenses General and administrative expenses were $1.6 million for the three months ended March 31, 2026, a decrease of approximately $0.9 million from $2.5 million for the three months ended March 31, 2025. #### Other Expenses (Income) Other expenses (income) were $0.1 million for the three months ended March 31, 2026, compared to - $0.0 million for the three months ended March 31, 2025. #### Net Gain from Deconsolidation of Subsidiary A net gain from deconsolidation of subsidiary was $1.9 million for the three months ended March 31, 2026, with no comparable amount in the prior year period. #### Interest Expenses Interest expenses were - $0.2 million for the three months ended March 31, 2026, compared to - $0.0 million for the three months ended March 31, 2025. #### Day One Loss Upon Entering Transaction Day one loss upon entering transaction was - $5.2 million for the three months ended March 31, 2026, with no comparable amount in the prior year period. #### Loss (Income) from Change in Derivatives Financial Instruments Measured at Fair Value Loss from change in fair value of derivatives was - $14.1 million for the three months ended March 31, 2026, compared to an income of $0.9 million for the three months ended March 31, 2025. #### Finance Expense, Net Finance expense, net, was - $0.4 million for the three months ended March 31, 2026, compared to - $0.8 million for the three months ended March 31, 2025. #### Tax Expenses Tax expenses were $0 for the three months ended March 31, 2026, compared to - $0.0 million for the three months ended March 31, 2025. #### Cash, Cash Equivalents, and Restricted Cash Cash, cash equivalents, and restricted cash were $1.2 million as of March 31, 2026, down from $5.0 million as of December 31, 2025. #### Net Cash Used in Operating Activities Net cash used in operating activities was - $5.4 million for the three months ended March 31, 2026, compared to - $8.7 million for the three months ended March 31, 2025. #### Net Cash Used in Investing Activities Net cash used in investing activities was - $1.0 million for the three months ended March 31, 2026, compared to $0.1 million provided by investing activities for the three months ended March 31, 2025. #### Net Cash Provided by Financing Activities Net cash provided by financing activities was $2.6 million for the three months ended March 31, 2026, compared to $11.9 million for the three months ended March 31, 2025. #### Accumulated Deficit The accumulated deficit was approximately - $236.0 million as of March 31, 2026, compared to approximately - $216.9 million as of December 31, 2025. #### Capital Deficiency Total capital deficiency was - $0.9 million as of March 31, 2026, an improvement from - $1.3 million as of December 31, 2025. #### Current Liabilities Trade account payables were $0.7 million as of March 31, 2026, down from $3.1 million as of December 31, 2025. Other account payables were $0.5 million as of March 31, 2026, down from $1.8 million as of December 31, 2025. #### Other Current Assets Other current assets increased to $1.9 million as of March 31, 2026, from $0.5 million as of December 31, 2025. #### Warrants The fair value of warrants was $1.7 million as of March 31, 2026, compared to $0.7 million as of December 31, 2025. #### Operating Costs by Type (Three Months Ended March 31) Salaries and related expenses (excluding share-based compensation) were $1.8 million in 2026, down from $2.0 million in 2025. Clinical trials expenses were $0.1 million in 2026, significantly lower than $3.6 million in 2025. Stock-based compensation was - $1.9 million in 2026, compared to $0.7 million in 2025. Depreciation expenses were $0 in 2026, compared to $0.2 million in 2025. Insurance costs were $0.8 million in 2026, with no comparable amount in 2025. Other segment items were $0.5 million in 2026, down from $1.3 million in 2025. ### Outlook BiomX Inc. anticipates continued operating losses in the near future, despite expecting to generate revenue from new operating subsidiaries (DFSL and ZorroNet) and X Security’s distribution arrangements starting in Q2 2026. The company’s ability to fund operations beyond the next several months depends on securing additional financing or generating sufficient operating cash flows from newly acquired subsidiaries, which is not assured. BiomX Inc. plans to pursue future equity or debt issuances, utilize the Mandragola credit line, and seek additional government grants to support operations and integrate new acquisitions. ### Related Stocks - [PHGE.US](https://longbridge.com/en/quote/PHGE.US.md) ## Related News & Research - [BiomX Delays Quarterly Report Amid Strategic Shift](https://longbridge.com/en/news/286624580.md) - [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Gentoo Media publishes Q1 2026 interim report](https://longbridge.com/en/news/287169902.md) - [Financial year ending 31 March 2026 reports final results.](https://longbridge.com/en/news/287166907.md)